
Background: Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy, microvascular dysfunction and chronic energetic inefficiency. Current therapies relieve symptoms or left ventricular outflow tract obstruction but do not directly target these metabolic abnormalities. Methods: We systematically searched PubMed, Embase, Google Scholar and ClinicalTrials.gov from 1 January 2000 to 31 May 2025 for randomised trials, observational cohorts, registries and case series (≥3 patients) evaluating fatty acid oxidation inhibitors (perhexiline, trimetazidine), late sodium current inhibition (ranolazine) or sodium–glucose cotransporter 2 inhibitors (SGLT2I) in adults with HCM. Outcomes included exercise capacity, diastolic indices, symptoms, arrhythmia burden and safety. Results: Seven HCM-specific studies met inclusion criteria: trimetazidine (one randomised controlled trial [RCT]), perhexiline (one RCT), ranolazine (one RCT, one real-world cohort and one case series) and SGLT2I (one prospective controlled cohort, one nationwide registry). Most enrolled predominantly non-obstructive or mixed HCM. Trimetazidine had neutral effects on peak VO₂, diastolic function and biomarkers. Perhexiline improved phosphocreatine-to-adenosine triphosphate ratios, diastolic indices, peak VO₂ and New York Heart Association class. Ranolazine consistently reduced angina and ventricular ectopy but did not increase peak VO₂. In the included HCM studies, empagliflozin/dapagliflozin exposure in a small prospective cohort was associated with improved E/e′ and New York Heart Association class, while broader SGLT2I use in a diabetic HCM registry was associated with lower mortality and hospitalisation for heart failure. Conclusion: Metabolic modulators and SGLT2I could improve diastolic parameters, symptoms and arrhythmia burden in selected, mainly non-obstructive HCM populations but have not demonstrated consistent gains in exercise capacity. Larger, phenotype-stratified randomised trials are needed to define their role alongside contemporary HCM therapies.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy increasingly recognised as a cause of heart failure. Advances in the understanding of its pathophysiology have enabled the development of targeted therapies, making ATTR-CM a paradigm of precision medicine in cardiology. Currently approved disease-modifying therapies, including two stabilisers (tafamidis and acoramidis) and one gene-silencing agent (vutrisiran), slow disease progression and reduce hospitalisations and mortality, particularly when initiated early. Because these therapies do not reverse established amyloid deposition, supportive management remains a critical component of care and presents distinct challenges. These include universal anticoagulation in AF, careful diuretic management, the benefits of sodium–glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists, and limited tolerance to other foundational heart failure therapies. On-going intensive research is expanding the therapeutic landscape, with several Phase III trials evaluating next-generation silencers, gene-editing strategies and amyloid-removal therapies. While these advances hold promise for disease reversal and prevention, important unresolved issues arise, including optimal treatment selection, monitoring strategies and economic sustainability.
Background: Optimal antiplatelet therapy after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) requires balancing thrombotic protection and bleeding risk, but the comparative effectiveness of current strategies remains uncertain. Aims: To evaluate the risk–benefit profile of oral antiplatelet strategies after PCI with DES, focusing on major bleeding and stent thrombosis. Methods: A network meta-analysis of randomised and observational studies was conducted. Strategies included standard or extended dual antiplatelet therapy (DAPT), shortened DAPT followed by monotherapy and P2Y12 inhibitor-based monotherapy. Outcomes were analysed using a random-effects model and ranked with p-scores. Evidence certainty was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: Thirty studies involving 110,035 patients were included. Ticagrelor monotherapy ranked highest for reducing major bleeding, whereas extended DAPT provided the greatest protection against stent thrombosis, with clopidogrel-based therapy beyond 12 months ranking highest (RR 0.08; 95% CI [0.01–0.52]; p-score=0.94). Notably, clopidogrel monotherapy after prolonged DAPT demonstrated a relatively balanced profile across both outcomes. However, no strategy was consistently optimal and most estimates showed wide CIs. Conclusion: Antiplatelet strategies after PCI with DES involve a clear trade-off between bleeding and thrombotic risk. Clopidogrel monotherapy after prolonged DAPT may offer a balanced approach, although findings should be interpreted cautiously due to limited precision and consistency.